$EYEG News
Last published 2y ago
- 2y agoABBUFCTAFMTAFL+2AllianceBernstein Launches Five New Active ETFsPR NewswireAllianceBernstein Holding L.P. (NYSE: AB) and AllianceBernstein L.P., a leading global investment management and research firm, announced today the...
- 5y agoEYEGKPRXEyeGate is Now Kiora Pharmaceuticals; Provides Update on Company's Sharpened Clinical Development StrategyGlobeNewswireSALT LAKE CITY, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX), ("Kiora" or the "Company") is the new name of EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG). Kiora will trade on the Nasdaq Capital Market under the ticker symbo
- 5y agoEYEGEyeGate Pharmaceuticals Appoints Eric J. Daniels, MD, MBA, as Chief Development Officer and Closes Acquisition of Bayon Therapeutics, Inc.GlobeNewswireWALTHAM, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG), ("EyeGate" or the "Company"), a clinical stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, tod
- 5y agoEYEGLICYSDCSEAC+1Thinking about buying stock in SeaChange, SmileDirectClub, Li-Cycle, Wheels Up, or Eyegate Pharmaceuticals?PR NewswireNEW YORK, Sept. 14, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SEAC, SDC, LICY, UP, and EYEG. To
- 5y agoEYEGEyeGate to Present at the H.C. Wainwright 23rd Annual Global Investment ConferenceGlobeNewswireWALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG), ("EyeGate" or the "Company"), a clinical-stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, t
- 5y agoEYEGEyeGate Pharma Completes Target Enrollment in Phase 2 Proof-of-Concept Study to Evaluate PP-001 for the Treatment of Ocular Surface InflammationGlobeNewswire-Proof-of-concept study conducted in Austria; Study designed to build upon positive Phase 1 safety data in healthy volunteers- -Trial remains on track with topline data expected in Q4 2021- WALTHAM, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Eye
- 5y agoEYEGEyeGate Pharma Reports Second Quarter 2021 Financial Results and Provides Business UpdateGlobeNewswireWALTHAM, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG), ("EyeGate" or the "Company"), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on
- 5y agoEYEGEyeGate Announces Closing of $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesGlobeNewswireWALTHAM, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or the "Company"), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on t
- 5y agoEYEGEyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesGlobeNewswireWALTHAM, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or the "Company"), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on t
- 5y agoADTXCERCEYEGMOGU+1Thinking about buying stock in Eyegate Pharmaceuticals, Mogu, Aditxt, Powerbridge Technologies, or Cerecor?PR NewswireNEW YORK, July 27, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EYEG, MOGU, ADTX, PBTS, and CERC.
- 5y agoEYEGEyeGate Pharmaceuticals Announces Appointment of Brian M. Strem, Ph.D., as President and Chief Executive OfficerGlobeNewswireWALTHAM, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG), ("EyeGate" or the "Company"), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on
- 5y agoEYEGEyeGate Pharma Announces First Patient Dosed for PP-001 in a Phase 2 Proof-of-Concept Ocular Surface Inflammation StudyGlobeNewswire- Proof-of-concept study conducted in Austria--Topline data expected in Q4 2021- WALTHAM, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG), ("EyeGate" or the "Company"), a clinical-stage company developing and com
- 5y agoEYEGEyeGate Pharma Reports First Quarter 2021 Financial Results and Provides Business UpdateGlobeNewswire- PP-001: proof-of-concept study in Austria for dry eye patients expected to initiate in Q3:21; U.S. IND submission planned in Q4:21- -OBG: U.S. IND submission and initiation of Phase 2 dry eye study is planned in Q4:21; proof-of-concept study for per
- 5y agoEYEGEyeGate Pharma Announces the Appointment of Kenneth Gayron and Aron Shapiro to its Board of DirectorsGlobeNewswireWALTHAM, Mass., April 01, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing products for treating inflammatory...
- 5y agoEYEGEyeGate Pharma Reports Full Year 2020 Financial Results and Provides Business UpdateGlobeNewswireWALTHAM, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for...
- 5y agoEYEGEyeGate Pharmaceuticals Announces Management Transition In Support of Strategic TransformationGlobeNewswire- Franz Obermayr, Ph.D. Appointed as Acting Chief Executive Officer, Transitioning From EVP Clinical Development - - Stephen From Elevated from Chief Executive Officer to Executive Chairman - ...
- 5y agoEYEGEyeGate Enters Into Agreement for $8.0 Million Private PlacementGlobeNewswireWALTHAM, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for...
- 5y agoEYEGEyeGate Pharma Announces Transformative Acquisition of Panoptes PharmaGlobeNewswireExpands Pipeline Beyond Ophthalmology with PP-001, a Clinical Stage, Best-in-Class DHODH Inhibitor PP-001 Leverages a Validated Immune Modulating Mechanism Optimized for Increased Specificity and...
- 6y agoEYEGEyeGate Pharma Reports Third Quarter 2020 Financial Results and Provides Business UpdateACCESS NewswireEyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of the eye, today announced financial results for the quarter ended September 30, 2020 and provided an update on recent corporate and operational activities.
- 6y agoEYEGNew patent application published for: Compositions and Methods for Treatment of Ocular DiseasesUS Patent Applications (USPTO)
- 6y agoEYEGEyeGate Pharma to Present at H.C. Wainwright 22nd Annual Global Investment ConferenceACCESS NewswireEyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that its Chief Executive Officer, Stephen From, will be presenting at the H.C. Wainwright 22nd Annual Global Investment Conference, taking place from September 14-16th, 2020.
- 6y agoEYEGEyeGate Pharma Confirms Path Forward with FDA To Develop Combination ProductACCESS NewswireEyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that it has received positive feedback following its pre-IND meeting with the U.S. Food and Drug Administration ("FDA") and has been provided a path forward for the development of MoxiGel, a combination product for the ...
- 6y agoEYEGEyeGate Pharma Reports Second Quarter 2020 Financial Results and Provides Business UpdateACCESS NewswireEyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of the eye, today announced financial results for the quarter ended June 30, 2020 and provided an update on recent corporate and operational activities.
- 6y agoEYEGEyeGate Pharma to Proceed with PE Pivotal StudyACCESS NewswireEyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that based on feedback from a meeting with the U.S. Food and Drug Administration ("FDA"), EyeGate can move forward with the filing of an IDE for a punctate epitheliopathies ("PE") pivotal study.
- 6y agoEYEGEyeGate Pharma Receives Positive Feedback from FDA Regarding Ocular Bandage Gel PackagingACCESS NewswireWALTHAM, MA / ACCESSWIRE / June 11, 2020 / EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that it has received positive feedback from the U.S. Food and Drug Administration ("FDA") regarding the requested packaging for EyeGate's Ocular Bandage Gel ("OBG") eye drop.
- 6y agoEYEGEyeGate Pharma to Present at Jefferies 2020 Virtual Healthcare ConferenceACCESS NewswireEyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that its Chief Executive Officer, Stephen From, will be presenting at Jefferies Virtual Healthcare Conference, taking place from June 2-4, 2020.
- 6y agoEYEGEyeGate Pharma Reports First Quarter 2020 Financial Results and Provides Business UpdateACCESS NewswireWALTHAM, MA / ACCESSWIRE / May 6, 2020 / EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of the eye, today announced financial results for the quarter ended March 31, 2020 and provided an update on recent corporate and operational activities.